Mondobiotech in merger negotiations with Pierrel


Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and life science industries, Pierrel SpA, with regard to a potential combination of the Contract Research Organization (CRO) of Pierrel with Mondobiotech. According to a non-binding letter of intent signed by the parties, the business combination should be structured by way of a contribution in kind of 100% of the share capital of Pierrel Research International AG (the CRO holding company), fully owned by Pierrel into the capital of Mondobiotech, through a dedicated capital increase of the latter. The news led initially to a Mondobiotech share price rally at the SIX Swiss Exchange to a plus of 88 % (at 0.75 CHF) before falling back to 0.40 CHF. Last December, Mondobiotech announced that, due to the current financial market conditions and the lack of significant progress with currently available options, it would be implementing restructuring measures. Together with other fluctuations, this would include a reduction of more than 50% of the firm’s total workforce by the end of February 2012. Activities will be concentrated in the company’s Stans headquarters.



Basel/Würzburg – Scientists from Swiss Novartis AG have cracked the mechanism that leads to permanent activation of the immune system in course of atherosclerosis and have targeted an antibody against it in mice and humans (JCI,...



Basel - Scientists at Roche Holding AG's subsidiary Genentech have found a way to get antibodies across the blood-brain barrier that block the enzyme beta-secretase 1 which is believed to prevent formation of Alzheimer's plaques....



Allschwil – Swiss biotech firm Actelion Pharma has reached the primary endpoint of preventing allergic rhinitis symptoms in patients challenged with Mountain Cedar pollen in a proof-of-concept study with its oral CRTH2...



Basel – Swiss drugmaker Roche has filed for MAA in Europe and the U.S. for vemurafenib (RG7204, PLX4032 , RO5185426) in patients with malignant melanoma who carry the common B-Raf V600E mutation. The oral B-RAF blocker interrupts...



Basel – Novartis COPD drug NVA237 (glycopyrronium bromide) has met the primary endpoint of superior bronchodilation to placebo at 12 weeks in a Phase III study with 800 participants, according to the Swiss drug giant’s...



Zurich – Researchers under Prof Dario Neri from ETH Zurich have presented a new approach that cured squamous cell carcinoma in two mouse models (Br. J Cancer, doi: 10.1038/bjc.12.04.11). The founder of the biotech firm Philogen,...



Zurich – Swiss Novartis AG has discontinued a Phase III head-to-head comparison of Tasigna (nilotinib) with the company’s US-$4 million blockbuster Glivec (imatinib) as first-line treatment of gastrointestinal stromal tumours...

Displaying results 41 to 50 out of 276

< Previous 41-50 Next >

© 2007-2015 BIOCOM



All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%


  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015

Current issue

All issues